New drugs for methicillin-resistant Staphylococcus aureus skin and soft tissue infections
| Autor: | Joya-Rita Hindy, Sara Haddad, Souha S. Kanj |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Methicillin-Resistant Staphylococcus aureus
Microbiology (medical) Staphylococcus aureus medicine.medical_specialty medicine.drug_class Antibiotics medicine.disease_cause chemistry.chemical_compound Telavancin Omadacycline Humans Medicine Intensive care medicine business.industry Soft Tissue Infections Oritavancin Dalbavancin Staphylococcal Infections biochemical phenomena metabolism and nutrition bacterial infections and mycoses Methicillin-resistant Staphylococcus aureus Anti-Bacterial Agents Community-Acquired Infections Infectious Diseases chemistry Staphylococcal Skin Infections Tedizolid Delafloxacin business medicine.drug |
| Zdroj: | Current Opinion in Infectious Diseases. 35:112-119 |
| ISSN: | 1473-6527 0951-7375 |
| Popis: | Purpose of review Staphylococcus aureus is a pathogen incriminated in skin and soft tissue infections (SSTIs), with methicillin-resistant S. aureus (MRSA) becoming the predominant cause and representing a significant burden to the healthcare system. The last updated Infectious Diseases Society of America (IDSA) guidelines concerning MRSA infections and SSTIs management were published in 2011 and 2014, respectively. The UK updated guidelines for MRSA infection treatment were published in 2021. Older treatment options may be associated with toxicity and require frequent dosing. There is a paucity of recent reviews on the armamentarium of new agents for MRSA SSTIs treatment. Recent findings Since 2005, several new antibiotics received a fast-track approval by the Food and Drug Administration (FDA) for SSTI treatment. These drugs include delafloxacin, omadacycline, tedizolid, ceftaroline, dalbavancin, oritavancin and telavancin. In this manuscript, we will review the data that led to these new drugs approval and discuss their advantages and disadvantages in MRSA SSTIs management. Summary MRSA is a major cause of SSTIs. Several novel therapies covering MRSA were FDA-approved for SSTIs. However, the current IDSA guidelines for MRSA infection and SSTIs as well as the recently published UK guidelines on MRSA treatment only consider these drugs as alternative choices or do not mention them at all. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|